Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Outcomes of haploidentical transplantation with umbilical cord blood co-infusion in aplastic anemia: Clinical and single-cell insights

Yu Zhang, Qijia Zheng, Nanxi Dong et al. Nov 03, 2025 pp. 7777-7777 10.1182/blood-2025-7777

Abstract Aplastic anemia (AA) is a life-threatening disorder characterized by pancytopenia and bone marrow failure. Hematopoietic stem cell...

Monocyte-T cells crosstalk orchestrates early graft-versus-leukemia immunity in Acute Myeloid Leukemia patients after allogeneic transplantation

Weiqian Dai, Linjie Wu, Xueying Zhao et al. Nov 03, 2025 pp. 594-594 10.1182/blood-2025-594

Abstract Background Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Hematopoietic stem cell transplantation (HSCT)...

Discovery of JAK2V617F mutant specific allosteric inhibitors for the treatment of myeloproliferative neoplasms

Anil Padyana, Bingsong Han, Hongling Yuan et al. Nov 03, 2025 pp. 1977-1977 10.1182/blood-2025-1977

Abstract The V617F mutation in Janus Kinase 2 (JAK2V617F) is a recurrent driver of myeloproliferative neoplasms (MPNs), including myelofibro...

Dissecting India's molecular hematology landscape: A 1000-patient genomic study identifies geographic clusters, signature enrichments, and young-onset AML

Rahul Bhargava, Shrinidhi Nathany, Hrithik Bagga et al. Nov 03, 2025 pp. 962-962 10.1182/blood-2025-962

Abstract Genomic data on hematologic malignancies from low- and middle-income countries (LMICs) remain sparse. India, with its diverse ances...

Late recurrence of transfusion dependent thalassemia 30 years after transplantation

Emanuele Angelucci, Stella Santarone, Luca Malcovati et al. Nov 03, 2025 pp. 7789-7789 10.1182/blood-2025-7789

Abstract Here we report 5 cases of patients transplanted in the eighties/early nineties who experienced an unexpected, unheralded, and unexp...

Trends and predictors of inpatient mortality in patients with aplastic anemia: A 7-year national inpatient sample analysis

Najam Gohar, Muhammad Usman, Haris Tahir et al. Nov 03, 2025 pp. 6724-6724 10.1182/blood-2025-6724

Abstract Background:Aplastic anemia (AA) is a rare but serious hematologic disorder that results from immune-mediated destruction of hematop...

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

Marlise Luskin, Andrea Damon, Emily McGovern et al. Nov 03, 2025 pp. 5097-5097 10.1182/blood-2025-5097

Abstract Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is the predominant genetic ALL subtype in adult...

Association between obesity and venous thromboembolism in hospitalized patients with multiple myeloma - perspective from national inpatient sample (NIS) database

Aman Ullah, Muhammad Zahid, Naima Shakeel et al. Nov 03, 2025 pp. 7917-7917 10.1182/blood-2025-7917

Abstract Background: Patients with multiple myeloma (MM) have a high risk of venous thromboembolism (VTE) due to disease and treatment relat...

Molecular and clinical characteristics of NUP98 rearrangements and their therapeutic responses in 6,000 patients with hematologic malignancies

Bingqing Huang, Yujiao Jia, Haoxu Wang et al. Nov 03, 2025 pp. 3469-3469 10.1182/blood-2025-3469

Abstract Background: Translocations involving nucleoporin 98 (NUP98) and over 30 fusion partner genes are well-characterized drivers of hemat...

Biomarkers for venous thromboembolism in children with central venous catheters

Neha Bhasin, Han Pham, Shravan Kannan et al. Nov 03, 2025 pp. 3125-3125 10.1182/blood-2025-3125

Abstract Background The incidence of venous thromboembolism (VTE) in children has been increasing by about 10% per year...

A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM

Lekha Mikkilineni, Jennifer Mann, Genevieve Fromm et al. Nov 03, 2025 pp. 4162-4162 10.1182/blood-2025-4162

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has transformed the treatment...

Disruption of intestinal homeostasis reflected by DAO and microbiota alterations in gvhd post-HSCT.

Saori Shimoyama-Ibuki, Satoshi Iyama, Shotaro Shirato et al. Nov 03, 2025 pp. 2457-2457 10.1182/blood-2025-2457

Abstract Introduction Graft-versus-host disease (GVHD) is a serious complication that markedly influences the prognosis of patients undergoi...

Mednext-based automatic segmentation of 18F-FDG PET images in angioimmunoblastic T-cell lymphoma and prognostic value exploration of predicted Total metabolic tumor volume

Xinyuan Chen, Bing Chen, Jingyan Xu Nov 03, 2025 pp. 7168-7168 10.1182/blood-2025-7168

Abstract Objective:To evaluate MedNeXt, a deep learning network, for automated segmentation of 18F-FDG PET images in angioimmunoblastic T-ce...

Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism

Marie-Claude Pelland-Marcotte, Thai Hoa Tran, Chantal Éthier et al. Nov 03, 2025 pp. 3123-3123 10.1182/blood-2025-3123

Abstract Background: Venous thrombo-embolism (VTE) occurs in up to 10% of pediatric patients with acute lymphoblastic leukemia (ALL). While a...

Real-world effectiveness of belumosudil for chronic GVHD by line of treatment: Analysis of academic and community practice patterns

Aleksandr Lazaryan, Kevin Hall, Catherine Lee et al. Nov 03, 2025 pp. 7771-7771 10.1182/blood-2025-7771

Abstract Introduction: Belumosudil (BEL) is a ROCK2 inhibitor approved by the US FDA for the treatment of steroid-refrac...

Disease stigma and salivary stress biomarkers among adolescents and young adults with sickle cell disease

Kemar Prussien, Margaret Mary Burke, Sana Bakir et al. Nov 03, 2025 pp. 2670-2670 10.1182/blood-2025-2670

Abstract Introduction: Disease stigma is a known psychosocial stressor that impacts adolescents and young adults (AYA) living with sickle ce...

Renal and urinary adverse events following CAR-t therapy: A faers-based pharmacovigilance analysis

Kevin Zhu, James Gerson, Rohit Singh Nov 03, 2025 pp. 2364-2364 10.1182/blood-2025-2364

Abstract Background: CAR-T therapy is a transformative treatment for relapsed hematologic malignancies and is being explored for autoimmune...

A prospective non-randomized controlled study of vaseline-medicated gauze for topical management of chemotherapy-induced oral mucositis in pediatric hematology patients

Jing Pan, Xiaoyuan Wu, XuNan Chen et al. Nov 03, 2025 pp. 5107-5107 10.1182/blood-2025-5107

Abstract Background: Chemotherapy-induced oral mucositis (CIOM) is a severe complication in pediatric hematologic malignancies, leading to t...

Palliative care consultation reduces hospital costs and length of stay among decedents with hematologic malignancies: A propensity score matched analysis from the national inpatient sample, 2016-2022

Benedict Amalraj, Mariana Marrero Castillo, Yousef Hasan Nov 03, 2025 pp. 4412-4412 10.1182/blood-2025-4412

Abstract Introduction: Patients with hematologic malignancies face unique end-of-life challenges including rapid clinical deterioration, ong...

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Nicola Polverelli, Annalisa Chiappella, Mauro Krampera et al. Nov 03, 2025 pp. 3722-3722 10.1182/blood-2025-3722

Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory B-cell lymphomas....

Children and adolescents with sickle cell disease demonstrate improved health-related quality of life and low decisional regret after hematopoietic cell transplantation: A sickle cell transplant advocacy and research alliance (STAR) study

Gregory Guilcher, Jenny Duong, Stephen Sands et al. Nov 03, 2025 pp. 4278-4278 10.1182/blood-2025-4278

Abstract Hematopoietic cell transplantation (HCT) for pediatric sickle cell disease (SCD) has steadily increased, however data on long-term...

Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era

Mahija Cheekati, Danielle Thor, John Rutledge et al. Nov 03, 2025 pp. 4462-4462 10.1182/blood-2025-4462

Abstract Introduction Splenectomy is utilized in benign and malignant hematologic conditions such as immune thrombocytopenic purpura, autoim...

The constant burden-aplastic anaemia as the underlying cause of death in older US adults- half century insights from the CDC wonder database (1968-2023)

Aman Ullah, Aleena Sharif, Faseeh Haider et al. Nov 03, 2025 pp. 6726-6726 10.1182/blood-2025-6726

Abstract Introduction: Aplastic Anemia is a serious blood disorder affecting roughly 2 persons per million in United Sta...

PI3Kδ inhibition enhances trametinib efficacy by suppressing feedback-activated PI3K/AKT signaling in PTPN11-mutant JMML

Yuming Zhao, Yao Guo, Zhiyong Peng et al. Nov 03, 2025 pp. 5010-5010 10.1182/blood-2025-5010

Abstract Juvenile myelomonocytic leukemia (JMML) is a rare but aggressive pediatric hematopoietic malignancy driven by mutations in the Ras...

Characterizing palliative care utilization among patients with Acute Myeloid Leukemia (AML): Insights from analysis of AML hospitalizations in the United States.

Oluwafemifola Oyedeji, Oladayo Oyebanji, Chinemerem Emeasoba et al. Nov 03, 2025 pp. 4622-4622 10.1182/blood-2025-4622

Abstract Introduction Acute Myeloid Leukemia (AML) is an aggressive form of hematological malignancy with an estimated five-year survival ra...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page